Implementation of the Fatty Liver Index in Primary Care

Consorci Sanitari de l'Alt Penedès i Garraf434 enrolled

Overview

This trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (Fatty Liver Index) in Primary Care. Medical teams in a primary care center will be divided into 2 groups, with one group using the screening test in their clinical practice. The number of interventions on cardiovascular risk occurring in patients attended by each group of medical teams will be evaluated and compared.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

434

Conditions

Hepatic Steatosis Overweight and Obesity

Interventions

FLIOTHER

Health professionals will use the FLI test in their clinical practice

Eligibility

Sex: ALLMin age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women aged 14 years and older. * Attended at the Basic Care Units (BCU) participating in the Primary Care Center Baix a Mar study. * Intention to undergo medical follow-up at the study center. * Body mass index ≥ 25. Exclusion Criteria: * Pregnant women * Alcohol consumption habit (Standard Drink Unit (SDU); one SDU equals 10 grams of alcohol. Risky consumption is considered from 4 SDUs in men and 2 SDUs in women). * Displaced patients not assigned to the study center. * Patients classified as Advanced Chronic Care Model or Complex Chronic Patient. * Participants diagnosed with any of the following pathologies: Chronic liver diseases, including hepatic steatosis; Dementia; Active oncological diseases * Cognitive or affective pathology that limits the ability to collaborate with lifestyle interventions carried out at the center. * Patients under the care of endocrinology specialists. * Participation in another clinical trial involving an experimental intervention during the period of this trial.

Locations (1)

Centro de Salud Vilanova i la Geltrú 3 Baix A Mar

Vilanova i la Geltrú, Barcelona, Spain

Outcomes

Primary Outcomes

Lifestyle Intervention

Percentage of participants receiving a lifestyle intervention from the start of the study to month 6

Time frame: Month 6

Secondary Outcomes

Low-density lipoprotein cholesterol

Value of low-density lipoprotein cholesterol (LDL cholesterol) in analyses performed between 6 months and one year post-intervention

Time frame: Month 12

Triglycerides

Value of triglycerides in analyses performed between 6 months and one year post-intervention

Time frame: Month 12

Gamma-glutamyl transpeptidase

Value of gamma-glutamyl transpeptidase in analyses performed between 6 months and one year post-intervention

Time frame: Month 12

Medical and nursing visits

Number of medical and nursing visits in the year following the intervention.

Time frame: Month 12

Analytical checks in the first year

Percentage of patients who had not undergone previous analytical checks according to protocol and who undergo analysis in the first year after the start of the study.

Time frame: Month 12

Lipid-lowering drugs

Number of prescriptions for lipid-lowering drugs.

Time frame: Month 12

Healthcare spending

Analysis of healthcare spending associated with each intervention, using billing data from the center associated with the use of resources by the insured party.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.